Expanding the paradigm of consolidation therapy in NSCLC and SCLC
23 Oct 2025
byProf. Te-Chun Hsia, China Medical University Hospital, Taichung, Taiwan
Concurrent chemoradiotherapy (cCRT) has long been the standard curative-intent treatment for stage III unresectable non-small-cell lung cancer (NSCLC) and limited-stage (LS) small-cell lung cancer (SCLC). Following cCRT, consolidation therapy with durvalumab, an anti–PD-L1 antibody, is considered the standard-of-care (SoC) for patients with stage III NSCLC with no actionable genomic alterations. However, uncertainty exists on consolidation therapy options with EGFR tyrosine kinase inhibitors (TKIs) for patients with EGFR-mutant NSCLC, given the established evidence supporting their use in both resectable and unresectable stages, as well as in LS-SCLC. At an industry-sponsored symposium, Professor Te-Chun Hsia of the China Medical University Hospital in Taichung, Taiwan, discussed evolving consolidation therapy strategies in lung cancer, highlighting the role of osimertinib, a third-generation EGFR TKI, in patients with unresectable stage III EGFR-mutated NSCLC, and durvalumab in those with LS-SCLC.
